妈妈咪呀

王星案细节公布：被贩卖至多个电诈园区！收到这样的招工信息需警惕_我的网站

一 |     1月17日，公安部发布消息，全力解救在泰缅边境失联被困中国公民，开展相关案件侦查调查。    Global consulting giant McKinsey & Company advised several painkillers producers for 15 years on how to "turbocharge" prescription drug sales largely to blame for starting the opioid epidemic in the US, The New York Times has revealed citing over 100,000 documents.,The docs emerged as a part of a settlement deal that McKinsey signed with several state attorneys that sued the company.,Apart from working with Endo, Purdue, and Mallinckrodt, the company also provided "in-depth experience in narcotics" for Johnson & Johnson subsidiaries producing controlled substances. Meanwhile, hundreds of thousands of US citizens died from overdose, often linked to these very drugs.,How It All Started,According to the disclosed documents, McKinsey helped both Endo and Purdue, the creators of two of the most widespread opioid-based drugs for severe chronic pain, to launch their products Opana and OxyContin in 2006-2008. The firm even advised one of the companies on how to overcome a Food and Drug Administration (FDA) block which it had encountered in 2008.,The FDA blocked Purdue's attempt to release an upgraded version of its OxyContin, which was more difficult to snort or dilute and inject in bloodstream – two methods of the prescription drug's abuse that already had been devised by some of its recipients. In order to help Purdue get the license, McKinsey interviewed an ex-drug dealer on the medication's abuse, prepared docs and even coached the drug firm's officials for meetings with the FDA as the pharmaceutical company knew its drug had been widely abused, the docs suggest.,Crack Pipes: Biden Administration's Handling of US Opioid Crisis Raising Questions, Journo Says15 February, 13:00 GMT,Purdue's main competitor, Endo, also released a new version of its painkiller and tried to get it marked as resistant to crushing (for snorting) and diluting (for injections), but the FDA did not allow the latter citing lack of such properties. Nonetheless, the drug's release was a success and coincided with a drop in abuse-resistant OxyContin's sales.,This came, however, at a cost of local epidemics of previously unseen blood disorders in several US states in 2012 – patients were found to be anemic and suffered from kidney failure. Many of them admitted to abusing updated Opana – the new formulae indeed discouraged from snorting it, but still allowed injection abuse. However, the same component that prevented crushing took a great toll on those who tried to inject the drug to get a better high, leading to red blood cells' destruction and organ damage.,Going on the 'Offensive',The consulting company's involvement in the opioid crisis did not stop at helping the companies to launch their products – it also helped them to boost the sales.,While the pills like the ones produced by Endo, Purdue and Mallinckrodt were originally advertised as not causing additions, US doctors were not always prone to prescribing them, especially when a patient's pain was neither severe nor chronic. According to the revealed documents, McKinsey's consultants helped Purdue, and several other companies, including two J&J subsidiaries, to overcome this "problem".,Starting in 2009, McKinsey developed a "segmentation" strategy for Purdue: its analysts divided the company's customers into groups based on their potential thoughts of the product and then formed distinct messages for each group. The customers in this case were doctors prescribing painkillers and the product was opioid drugs. The strategy targeted even doctors who resorted to opioids only in most extreme cases, ensuring them of OxyContin's safety and trying to convince them that there was no point in making their patients suffer.,The consulting company proposed to achieve this by "[raising] physician comfort levels through appropriate education and support". Purdue tried to convince these doctors that their colleagues had no issues prescribing OxyContin.,By 2014, the US government started to realize a nascent opioid drug problem was underway and introduced new labeling requirements for such drugs as well as instructions to use them only in cases of severe of chronic pain. Around the same time, OxyContin sales started to decline, prompting Purdue to ask for McKinsey's help once again – this time to overcome the government's policy and precautions.,The consultants identified the problem as the company promoting its drug as a less potent opioid amid rampant drug abuse and advised to shift to the "offense" instead, the documents show. They namely advised focusing the salesmen efforts on doctors, who were likely to prescribe OxyContin to a new client not previously taking opioid drugs.,"Physicians with higher OxyContin NBRx to Rx ratio may be more likely to initiate a patient on OxyContin", an extract from a McKinsey presentation for Purdue from January 2014 said.,Around the same time and amid the 2015 HIV concentrated outbreaks in several states linked to the opioid drugs abuse via injections, McKinsey consulted Endo on promoting its Opana. The company was not concerned about what the CDC named "explosive transmission" of HIV and the Opana's role in it, according to the documents. On the contrary, in summer 2015, it helped Endo rededicate most of its salesmen from other products into a "Sales Force Blitz" – the company almost solely dedicated to selling Opana to around 3,000 physicians in the US.,One of McKinsey's consultants was excited over the creation of the "Force", claiming in correspondence with the head of Endo’s painkiller unit that the "fun [begins] on Monday!" with the latter responding "agreed, the fun is just beginning".,Playing Both Sides,One of the strangest revelations in the documents uncovered by the New York Times is that McKinsey managed to play both sides of the opioid crisis tragedy – helping pharmaceutical companies sell more of "not-so-addiction-resistant" drugs, while also assisting the FDA, other government agencies and state governments, in the fight against the epidemic.,In 2017, the FDA finally decided to pull one of the drugs, the more potent Opana, from the market, but not until it made $844 million in revenue with help from McKinsey and played a role in the deaths of thousands of Americans, considered to be the victims of the opioid epidemic. Paradoxically, the same year, McKinsey Senior Partner Tom Latkovic lamented about doctors prescribing opioid painkillers left and right at a health care conference.,"Why do we continue to prescribe, dispense, pay for opioid prescriptions to people that we know, or at least we could know, have an incredibly high propensity to abuse them?" Latkovic wondered.,The bizarre divergence between what McKinsey was advising to the pharmaceutical companies and Latkovic's rhetoric is explained by the fact that he was not a member of the consulting company's pharmaceutical practice, which worked with pharma.,Instead, he and his team worked with state governments and health systems to pin down the ways of tackling the opioid crisis, The New York Times said citing two local officials, who used to work on the issue. Their work, however, was partly complicated by McKinsey's pharmaceutical wing, which wanted to greenlight their draft publications in case they could damage their clients.,North Carolina Rep. Claims Opioid Crisis 'Affects Every Community' in US Amid Drug Trafficking Surge19 December 2021, 01:36 GMT,Eventually in 2019, McKinsey finally stopped advising its top client, Perdue, but not until their ties became public during one of the litigations related to the opioid epidemic and initiated by US authorities. One such litigation eventually had McKinsey pay $600 million in settlement without admitting guilt, as well as release the documents related to its work with the pharmaceutical companies.。

二 | 同时，公布了王星案的细节：2024年12月29日，王某在微信群中看到一则赴泰国曼谷拍摄影片的通告，遂根据通告内容添加副导演“颜十六”微信，沟通赴泰国曼谷拍戏事宜。2025年1月3日凌晨，王某抵达泰国曼谷机场后，乘坐“颜十六”安排的车辆经泰缅边境被送入缅甸妙瓦底“阿波罗”园区，随后又被贩卖至“环亚”“凯旋”等多个电诈园区。12名境内外犯罪嫌疑人被抓获收到这些消息需警惕公安机关在全力查找解救失联、被困人员的同时，同步推进案件侦查调查工作，循线深挖出一个藏匿于缅甸妙瓦底、专门从事跨境人口贩运的犯罪集团。2024年12月以来，该犯罪集团在大量微信群中发布招聘演员、模特、剧组工作人员等虚假信息，通过为有意向人员购买机票、预订酒店、安排车辆等方式，将其诱骗至泰国境内后，再转运至缅甸妙瓦底，贩卖至各电诈园区。近期网上的多起相关人员境外失联、被困案件均与该犯罪集团有关。目前，中泰警方已联手抓获12名境内外犯罪嫌疑人，相关案件侦办及其他犯罪嫌疑人缉捕工作正在进行中。视频加载中...公安机关提醒：境外诈骗集团以“高薪工作、包吃包住、报销机票、专人接送”为诱饵，或以商务考察、免费旅游等名义，将境内人员诱骗至境外非法拘禁，从事电信网络诈骗等违法犯罪活动。请广大群众务必提高警惕，加强安全防范，切勿轻信境外高薪招聘、务工信息。如何避免落入“境外招工”陷阱？1.看到境外招工信息，首先可通过商务部官网查询相关派遣公司是否列入“国家对外劳务合作企业名录”，仅凭对方提供的表格资料，并不能证实公司的正规性。对外劳务合作企业的名单向社会公布，是可以查询到的。

三 | 在商务部官方网站“机构设置”里面，选“合作司”，“在线查询”里面有“对外劳务合作企业名录”，点击第一个“企业名单”，所有合规的有经营资质的企业都在里面，是按照省来统计的。2.各国劳务派遣政策存在差异，具体求职政策可以通过相关国家大使馆或官方网站进行求证。

四 | 3.任何旅游签证都不能等同于境外劳务签证，求职者需分清签证类型避免被蒙蔽。4.求职者应避免通过不知名网站和非官方注册的社交账号求职或缴费，谨慎提供个人信息。王星失联事件时间线梳理↓1月3日，中国驻泰使领馆接到当事人亲属来电，就当事人在湄索失踪事件向总领馆求助。总领馆就失联事宜处理方式进行了详细介绍，并与当事人亲属保持良好沟通。1月5日晚，有中国网友在社交媒体发帖称，中国籍演员王星在泰缅边境失联，此事引发两国社会广泛关注。1月6日，中国驻泰国清迈总领馆回应称正与泰国有关方面及家属密切沟通，积极提供必要的协助，全力查找当事人下落。1月7日，中国驻泰国清迈总领馆发布消息，称总领馆当日下午从泰国达府移民局获悉，该局已接到在泰缅边境失联的中国籍男演员，目前正在按规定进行相关询问工作。

五 | 1月7日，泰国达府警方接到BGF（缅甸边境卫队）副指挥官的报告，确认已找到失联中国演员王星。1月8日，泰国警方确认，王星被骗出国参与选角，经泰国前往邻国，但到达邻国后发现被骗。1月8日，泰国警方表示，王星正在接受泰方的调查，他暂时还不能接受探视或者离开泰国。

六 | 警方澄清他并没有受到人身伤害，网上流传的腿部受伤传言并不属实。1月8日，泰国国家警察总署督察长塔查猜接受泰媒采访表示，经初步调查确认中国籍男演员王星为人口贩运受害者，后续计划在1至2天内将其送回中国。1月11日，中国籍演员王星所乘回国航班抵达上海浦东国际机场。（来源：央视新闻）更多精彩资讯请在应用市场下载“极目新闻”客户端，未经授权请勿转载，欢迎提供新闻线索，一经采纳即付报酬。24小时报料热线027-86777777。

Current article:http://k8wb56e.saorongriwazhaofutouzhaojie.cfd/news/20260826_310022.html

Published on:04:45:58